reports
Verona Pharma: 2 directors
Two Directors at Verona Pharma sold 100,000 shares at 91.207USD. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Verona Pharma Announces June 2025 Investor Conference Participation
Verona Pharma Announces June 2025 Investor Conference Participation LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside chats at the following conferences in June 2025: Jefferies Global Healthcare ConferenceDate: Wednesday, June 4, 2025Time: 11:05 a.m. ET / 4:05 p.m. BSTLocation: New York, NY Goldman Sachs 46th Annual Global Healthcare ConferenceDate: Monday, June 9, 2025Time: 2:40 p.m. ET / 7:40 p.m. BSTLocation: Miami, FL A webcast of each conferenc...
Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies...
Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025 Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population LONDON and RALEIGH, N.C., May 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces ten posters including seven additional analyses from its Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease (“COPD”),...
Verona Pharma Reports First Quarter 2025 Financial Results and Provide...
Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre® net sales of $71.3 million (+95% vs Q4 2024) ~25,000 prescriptions filled in Q1 2025 Q1 2025 revenue exceeds operating expenses excluding non-cash charges Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., April 29, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the...
Verona Pharma to Report First Quarter 2025 Financial Results and Provi...
Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update LONDON and RALEIGH, N.C., April 15, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the first quarter ended March 31, 2025 on Tuesday, April 29, 2025 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: ...
Verona Pharma Announces Amended Strategic Financing with Oaktree and O...
Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS RIPSA interests repurchased Term loan facility increased to $450 million with more favorable terms Access to up to an additional $200 million LONDON and RALEIGH, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, has amended its existing strategic financing agreements by repaying the revenue interest purchase and sale agreement (“RIPSA”) and increasing the debt facility to $450 million on impro...
- Jonathan Moreland
WWW WOLVERINE WORLD WIDE INC.
SM SM ENERGY COMPANY
SIGI SELECTIVE INSURANCE GROUP INC.
PDFS PDF SOLUTIONS INC.
PAHC PHIBRO ANIMAL HEALTH CORPORATION CLASS A
OSUR ORASURE TECHNOLOGIES INC.
OPK OPKO HEALTH INC.
MTDR MATADOR RESOURCES COMPANY
ITCI INTRA-CELLULAR THERAPIES INC.
HII HUNTINGTON INGALLS INDUSTRIES INC.
FRPT FRESHPET INC
FFIN FIRST FINANCIAL BANKSHARES INC
DGII DIGI INTERNATIONAL INC.
CPS COOPER-STANDARD HOLDINGS INC.
CLRO CLEARONE
CINF CINCINNATI FINANCIAL CORPORATION
AKAM AKAMAI TECHNOLOGIES INC.
AFG AMERICAN FINANCIAL GROUP INC.
DGICA DONEGAL GROUP INC. CL A
CECE CECO ENVIRONMENTAL CORP.
OESX ORION ENERGY SYSTEMS INC.
NHC NATIONAL HEALTHCARE CORP.
PLBC PLUMAS BANCORP
JFR NUVEEN FLOATING RATE INCOME FUND
JELD JELD-WEN HOLDING INC.
CLF CLIFFS NATURAL RESOURCES INC.
VRNA VERONA PHARMA ADS
OCSL OAKTREE SPECIALTY LENDING CORPORATION
SNBR SLEEP NUMBER CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
QNBC QNB CORP.
PCG PG &E CORPORATION
RCUS ARCUS BIOSCIENCES
REZI RESIDEO TECHNOLOGIES
CXDO INC.
CMTV CREXENDO
PRG COMMUNITY BANCORP INC. VT
VMEO PROG HOLDINGS
ETO INC.
ECAT VIMEO INC
MAIA EATON VANCE TAX ADV GBL DIV OPPTY
PFHC BLACKROCK ESG CAP ALLOCATION TR
ETG MAIA BIOTECHNOLOGY INC
EVT PROFRAC HLDG CORP
SSII EATON VANCE TAX ADV GLB DIN INC
ADVM EATON VANCE TAX ADVANTAGED DIVID IN
ISPO SS INNOVATIONS INTERNATIONAL INC
EVM ADVERUM BIOTECHNOLOGIES INC.
INSPIRATO INCORPORATED
EATON VANCE INSD CALIF MUN BD FD
- Jonathan Moreland
HII HUNTINGTON INGALLS INDUSTRIES INC.
FRPT FRESHPET INC
CLRO CLEARONE
FBK FB FINANCIAL CORPORATION
JELD JELD-WEN HOLDING INC.
CLF CLIFFS NATURAL RESOURCES INC.
VRNA VERONA PHARMA ADS
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
NWPP NEW PEOPLES BANKSHARES INC.
REZI RESIDEO TECHNOLOGIES
CMTV INC.
PFHC COMMUNITY BANCORP INC. VT
ADVM PROFRAC HLDG CORP
CYCC ADVERUM BIOTECHNOLOGIES INC.
CYCLACEL PHARMACEUTICALS INC.
Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Resu...
Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025 Phase 2 programs in bronchiectasis and fixed-dose combination in COPD advance Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: ...
Verona Pharma Announces March 2025 Investor Conference Participation
Verona Pharma Announces March 2025 Investor Conference Participation LONDON and RALEIGH, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in March 2025: TD Cowen 45th Annual Health Care ConferenceDate: Monday, March 3, 2025Time: 11:10 a.m. ET / 4:10 p.m. GMTLocation: Boston, MA Leerink Partners 2025 Global Healthcare ConferenceDate: Monday, March 10, 2025Time: 8:40 a.m. ET / 1:40 p.m. GMTLocation: Miami, FL A webcast of each conferenc...
Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Re...
Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update LONDON and RALEIGH, N.C., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the fourth quarter and full year ended December 31, 2024 on Thursday, February 27, 2025 and host an investment community conference call at 9:00 a.m. EST / 2:00 p.m. GMT to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to ...
Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminar...
Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights Approximately $36 million and $42 million net product sales of Ohtuvayre for the fourth quarter and full year 2024, respectively More than 3,500 unique prescribers and over 16,000 prescriptions filled in 2024 across a broad COPD population Approximately 45% of Tier 1 HCPs prescribed Ohtuvayre LONDON and RALEIGH, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on re...
Verona Pharma Announces December 2024 Investor Conference Participatio...
Verona Pharma Announces December 2024 Investor Conference Participation LONDON and RALEIGH, N.C., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the following conferences in December 2024: Piper Sandler 36th Annual Healthcare ConferenceDate: Tuesday, December 3, 2024Time: 12:00 p.m. ET / 5:00 p.m. GMTLocation: New York, NY 7th Annual Evercore HealthCONx ConferenceDate: Wednesday, December 4, 2024Time: 3:00 p.m. ET / 8:00 p.m. GMTLocation: Miami, FL A webcast of eac...
Verona Pharma to Present at Jefferies London Healthcare Conference
Verona Pharma to Present at Jefferies London Healthcare Conference LONDON and RALEIGH, N.C., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 6:30 a.m. ET / 11:30 a.m. GMT. A webcast of the event will be available on the Events and Presentations link on the Investors page of the Company’s website, . For further information please contact: Verona Pharma plcTel: Victoria Stewart, Senior Direct...
Verona Pharma Reports Third Quarter 2024 Financial Results and Provide...
Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more than 2,200 unique prescribers and more than 5,000 prescriptions filled across a broad COPD population Pipeline expansion continues: Phase 2 programs enrolling Conference call today at 9:00 a.m. ET / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focuse...
Verona Pharma to Report Third Quarter 2024 Financial Results and Provi...
Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update LONDON and RALEIGH, N.C., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that it will report its financial results for the third quarter ended September 30, 2024 on Monday, November 4, 2024 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. GMT to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: ...
Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies i...
Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024 Data support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 in a broad COPD population LONDON and RALEIGH, N.C., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces four oral presentations and two posters on analyses from its successful Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease (“COPD”) will be presented at CHEST Annual Meet...
Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studie...
Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024 One oral presentation and three posters support Ohtuvayre™ (ensifentrine), as a first-in-class, selective, dual inhibitor of PDE3 and PDE4 LONDON and RALEIGH, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces one oral presentation and 3 posters on additional analyses from its successful Phase 3 ENHANCE studies with Ohtuvayre (ensifentrine) for the treatment of chronic obstructive pulmonary disease (“COPD”) ...
Verona Pharma Reports Second Quarter 2024 Financial Results and Provid...
Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update OhtuvayreTM (ensifentrine) now available; patient shipments started Strong balance sheet supports commercialization and pipeline expansion Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST LONDON and RALEIGH, N.C., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the second quarter ended June 30, 2024, and provides a corporate update. “We are ...
Verona Pharma to Present at 44th Annual Canaccord Growth Conference
Verona Pharma to Present at 44th Annual Canaccord Growth Conference LONDON and RALEIGH, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will present a company overview at the 44th Annual Canaccord Growth Conference on Tuesday, August 13, 2024, at 1:30 p.m. EDT / 6:30 p.m. BST. A webcast of the event will be available on the Events and Presentations link on the Investors page of the Company’s website, . For further information please contact: Verona Pharma plcTel: Victoria Stewart, Senior Dire...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.